Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

3.0K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Recommendations on Home Maintenance Nebulization with Focus on Obstructive Airway Diseases: An Update on Best Practices and Future Directions.

The Journal of the Association of Physicians of India·2025
Same author

Evaluation for the Risk of Allergy to COVID-19 Vaccines in People with History of Allergy Diathesis.

The Journal of the Association of Physicians of India·2025
Same author

Performance of Clinical and Biochemical Parameters in Identifying Renal Histopathology and Predictors of One-Year Renal Outcome in Lupus Nephritis-A Single Centre Study from India.

Diagnostics (Basel, Switzerland)·2022
Same author

Hepatocellular Carcinoma Evaluation and Management for Physicians: Joint Gastroenterology Research Society and Association of Physicians of India Guidelines.

The Journal of the Association of Physicians of India·2022
Same author

Addressing Risk of Allergy following COVID-19 Vaccination in India - Reassure, Rethink and Revise.

The Journal of the Association of Physicians of India·2021
Same author

Impact of Autoantibodies to Complement Components on the Disease Activity in SLE.

The Journal of the Association of Physicians of India·2021

Related Experiment Video

Updated: May 3, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.7K

Biologics in SLE: the current status.

Anjali G Rajadhyaksha1, Sonal Mehra2, Milind Y Nadkar1

  • 1KEM Medical College, Mumbai.

The Journal of the Association of Physicians of India
|February 4, 2014
PubMed
Summary
This summary is machine-generated.

New biologic therapies targeting B-cells show promise for treating Systemic Lupus Erythematosus (SLE), offering new options for patients resistant to current treatments and managing disease flares.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.0K

Related Experiment Videos

Last Updated: May 3, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.7K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.0K

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic Lupus Erythematosus (SLE) is a severe autoimmune disease with limited treatment options.
  • Current therapies like glucocorticoids often lead to dependence and toxicity.
  • B-cell abnormalities are central to SLE pathogenesis, driving autoantibody production.

Purpose of the Study:

  • To review biological drugs evaluated in clinical trials for SLE treatment.
  • To emphasize the outcomes and mechanisms of action for these novel therapies.
  • To assess the potential of biologics in managing refractory lupus.

Main Methods:

  • Review of open-label and randomized clinical trials of biologic agents in SLE patients.
  • Analysis of therapeutic targets including B-cell depletion, co-stimulation blockade, and cytokine inhibition.
  • Evaluation of efficacy, safety, and mechanisms of action of biological therapies.

Main Results:

  • Belimumab is nearing approval as a novel SLE treatment.
  • Biologic agents targeting B-cell pathways show encouraging results.
  • Some biologics have demonstrated efficacy with manageable side effects, while others faced challenges.

Conclusions:

  • Biological therapies represent a promising new avenue for treating refractory SLE.
  • Targeting specific immune pathways, particularly B-cells, offers potential for improved patient outcomes.
  • Ongoing research and clinical trials are crucial for advancing SLE treatment.